DE-INCYTE
21.8.2024 17:41:34 CEST | Business Wire | Press release
Incyte (Nasdaq: INCY) today announced that the Company will present key data from its oncology portfolio at the upcoming European Society of Medical Oncology (ESMO) Congress 2024, to be held September 13-17 in Barcelona and virtually.
"The data at ESMO underscore the progress across our oncology portfolio and the potential to impact patients where additional treatment options are needed. Notably, a Presidential Symposium will feature new, pivotal results from the Phase 3 POD1UM-303/InterAACT2 study of retifanlimab (Zynyz®) for the treatment of squamous cell anal carcinoma (SCAC). The POD1UM-303 data will support the supplemental Biologics License Application (sBLA) filing for retifanlimab in SCAC planned by year end 2024," said Pablo Cagnoni M.D., President, Head of Research and Development, Incyte. "We will also present new data on INCB123667, a potential first-in-class CDK2 inhibitor, which we believe has the potential to enhance outcomes and serve as a foundational treatment for platinum-resistant ovarian and other cancers."
Details on the abstracts accepted for presentation at ESMO include:
Presidential Symposium
Retifanlimab (PD-1)
POD1UM-303/InterAACT2: Phase 3 Study of Retifanlimab With Carboplatin-Paclitaxel (C-P) in Patients (Pts) With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal (SCAC) Not Previously Treated With Systemic Chemotherapy
Presidential Symposium I: Practice-changing trials. Presentation Number: LBA2. Presentation Time: 10:50-11:02 a.m. ET (4:50-5:02 p.m. CET), September 14, 2024
Mini Oral Session
INCB123667
Safety and Tolerability of INCB123667, a Selective CDK2 Inhibitor, in Patients (Pts) With Advanced Solid Tumors: A Phase 1 Study
Mini oral session: Developmental therapeutics. Presentation Number: 617MO. Presentation Time: 9:35 – 9:40 a.m. ET (3:35-3:40 p.m. CET), September 14, 2024
Conference Call and Webcast
Incyte will host an in-person analyst and investor event on Saturday, September 14, 2024, from 1:00-2:30 p.m. ET (7:00-8:30 p.m. CEST) to discuss key data presentations at ESMO including data from the POD1UM-303 Presidential Symposia and its CDK2 inhibitor program. The CDK2 data presentation will include new results from a later data cut-off, as well as the data included in the ESMO accepted abstract and mini-oral presentation. The event will be webcasted and can be accessed via the Events and Presentations tab of the Investor section of Incyte.com and it will be available for replay for 90 days.
Conference call details will be provided on the Investor section of Incyte.com.
Abstracts will be available to registered attendees on the ESMO Virtual Congress platform beginning on September 9, 2024. All accepted abstracts will be published in the ESMO Congress 2024 Abstract Book, a supplement to the official ESMO journal, Annals of Oncology.
More information regarding the 2024 ESMO Congress can be found at https://www.esmo.org/meeting-calendar/esmo-congress-2024.
About Retifanlimab (Zynyz®)
Retifanlimab (Zynyz®), is an intravenous PD-1 inhibitor indicated in the U.S. for the treatment of adult patients with metastatic or recurrent locally advanced Merkel cell carcinoma (MCC). This indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.
Zynyz is marketed by Incyte in the U.S. In 2017, Incyte entered into an exclusive collaboration and license agreement with MacroGenics, Inc. for global rights to retifanlimab.
Zynyz is a trademark of Incyte.
About Incyte
A global biopharmaceutical company on a mission to Solve On., Incyte follows the science to find solutions for patients with unmet medical needs. Through the discovery, development and commercialization of proprietary therapeutics, Incyte has established a portfolio of first-in-class medicines for patients and a strong pipeline of products in Oncology and Inflammation & Autoimmunity. Headquartered in Wilmington, Delaware, Incyte has operations in North America, Europe and Asia.
For additional information on Incyte, please visit Incyte.com or follow us on social media: LinkedIn, X, Instagram, Facebook, YouTube.
Incyte Forward-Looking Statements
Except for the historical information set forth herein, the matters set forth in this press release, including statements regarding the presentation of data from Incyte’s clinical development pipeline, the potential for retifanlimab and INCB123667 to positively impact patients and plans to submit an sBLA for retifanlimab in SCAC by year end 2024, contain predictions, estimates, and other forward-looking statements.
These forward-looking statements are based on our current expectations and are subject to risks and uncertainties that may cause actual results to differ materially, including unanticipated developments in and risks related to: unanticipated delays; further research and development and the results of clinical trials possibly being unsuccessful or insufficient to meet applicable regulatory standards or warrant continued development; the ability to enroll sufficient numbers of subjects in clinical trials and the ability to enroll subjects in accordance with planned schedules; determinations made by the FDA and regulatory agencies outside of the United States; the efficacy or safety of our products; the acceptance of our products in the marketplace; market competition; unexpected variations in the demand for our products and the products of our collaboration partners; the effects of announced or unexpected price regulation or limitations on reimbursement or coverage for our products; sales, marketing, manufacturing, and distribution requirements, including our ability to successfully commercialize and build commercial infrastructure for newly approved products and any additional new products that become approved; and other risks detailed from time to time in our reports filed with the U.S. Securities and Exchange Commission, including our annual report on Form 10-K and our quarterly report on Form 10-Q for the quarter ended June 30, 2024. We disclaim any intent or obligation to update these forward-looking statements.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240821420609/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Visa Renews Partnership Across Red Bull Formula One Teams19.2.2026 15:00:00 CET | Press release
Long‑term renewal deepens Visa’s presence across Red Bull F1 Teams with enhanced branding, fan access and client experiences Renewed partnership to expand support of Oracle Red Bull Racing and Visa Cash App Racing Bulls Visa (NYSE: V) today announced a multi‑year renewal and expansion of its global partnership with Red Bull F1 Team’s Oracle Red Bull Racing and Visa Cash App Racing Bulls. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260219542270/en/ Building on the groundbreaking partnership launched in 2024, the renewed agreement reinforces Visa’s commitment to one of the world’s fastest‑growing sports, while introducing significant new branding rights, enhanced hospitality assets and immersive experiential opportunities across both teams. Visa will also continue as a Title Partner of both Visa Cash App Racing Bulls Formula One Team and its F1 Academy Programme, further strengthening Visa’s presence on and off the grid. “T
Project B Taps Fashion Industry Veteran William Kim as Chief Lifestyle Officer19.2.2026 15:00:00 CET | Press release
Global basketball platform merges elite sport with fashion, design, and culture Project B, an elite global women’s and men’s basketball grand prix built for a new generation of athletes and fans, today announced the appointment of William Kim as Chief Lifestyle Officer. In this strategic role, Kim will lead Project B’s premium lifestyle business across merchandise, brand collaborations, and cultural partnerships as Project B expands across Europe, Asia, and the Americas to create the most premium cultural platform in global sport. “We are building a model designed for 2030 and beyond,” said Kim. “It starts with creating exceptional products. We’re sourcing the highest quality natural fibers for every moment in an athlete’s day and offering those same collections to the broader fan community. From design to supply chain to final consumer experience, we are operating with the same discipline and control as a luxury house, overseeing product, distribution, and brand experience holisticall
Aeris Integrates with Palo Alto Networks to Secure the Wireless IoT Blind Spot with Agentless, Global SASE19.2.2026 15:00:00 CET | Press release
Aeris, a leader in wireless management platforms, security services and connected vehicle programs, today announced it has completed its product integration with Palo Alto Networks Prisma SASE 5G and joined an extensive ecosystem of Palo Alto Networks Technology Partners to deliver intelligent and interoperable solutions that enable joint customers with turnkey integrations that help them more easily and confidently secure their digital transformation journey. The integration combines Aeris IoT Watchtower™ with Palo Alto Networks Prisma SASE 5G to transform how enterprises protect wireless IoT deployments, providing a single point of control to extend security to the wireless IoT edge. The integration provides Layer 7 security features, including Deep Packet Inspection (DPI) and Data Loss Prevention (DLP), across a global footprint. By validating interoperability between these platforms, Aeris and Palo Alto Networks allow businesses to reduce their attack surface and bring previously i
Fosway 9-Grid™ Analysis Identifies O.C. Tanner as Strategic Leader in the Talent & People Success Market19.2.2026 15:00:00 CET | Press release
O.C. Tanner, the global leader in employee recognition and culture solutions, is honored to be recognized once again as a Strategic Leader in the latest Fosway 9-Grid™ for Talent & People Success. This top industry placement from Fosway Group, Europe’s leading HR and talent analyst, reaffirms O.C. Tanner’s ongoing commitment to innovating employee engagement and workplace culture. Fosway’s independent analysis positions vendors based on performance, potential, market presence, total cost of ownership, and trajectory, helping HR leaders make informed decisions about workplace solutions. O.C. Tanner’s recognition reflects both the strength of its Culture Cloud® platform and its ability to support complex, enterprise-level needs with meaningful outcomes. “Being named a Strategic Leader by Fosway is a powerful validation of the impact our team is delivering for organizations around the world,” said Scott Sperry, President and CEO of O.C. Tanner. “Today’s talent environment demands culture-
Calvin Klein Fragrances announces ROSALÍA as the face of new euphoria elixirs19.2.2026 14:30:00 CET | Press release
Campaign fronted by the global superstar and brand ambassador explores the distinct universes of the three new parfums Calvin Klein, Inc., part of PVH Corp. [NYSE: PVH], and Calvin Klein Fragrances, a division of Coty Inc. [NYSE: COTY], today unveil GRAMMY® Award-winning singer-songwriter ROSALÍA as the face of euphoria elixirs, a new collection of three distinct parfum intense creations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260219549836/en/ Calvin Klein Fragrances announces ROSALÍA as the face of new euphoria elixirs. A daring new chapter of the iconic euphoria franchise, euphoria elixirs are a sensorial exploration of confidence, pleasure and sensuality. Embodied by global icon and Calvin Klein ambassador ROSALÍA, the campaign fuses movement and vivid color into a captivating exploration of freedom without limits. Known for her genre-defying sound and commanding visual artistry, ROSALÍA channels the fragrances’ m
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom